Lipigon Pharmaceuticals AB (publ) (STO:LPGO)

Market Cap	27.14M
Revenue (ttm)	10.29M
Net Income (ttm)	-27.00M
Shares Out	148.33M
EPS (ttm)	-0.18
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	3,202,206
Average Volume	4,557,539
Open	0.1880
Previous Close	0.1830
Day's Range	0.1710 - 0.1880
52-Week Range	0.0752 - 0.3695
Beta	0.74
RSI	73.93
Earnings Date	Aug 28, 2025

About Verve Therapeutics

Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company’s product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based i...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2010
• Employees: 7
• Stock Exchange: Nasdaq Stockholm
• Ticker Symbol: LPGO

Financial Performance

In 2024, STO:LPGO's revenue was 10.29 million, a decrease of -37.30% compared to the previous year's 16.41 million. Losses were -25.26 million, 108.3% more than in 2023.